Emgality market seen expanding on migraine demand and CGRP adoption

The Business Research Company says the global Emgality market is set for steady growth through 2035 as migraine prevalence rises and biologic therapies gain wider use. North America held the largest share in 2025, while the report flags preventive treatments, monthly injections, and new headache indications as key growth themes.

Why it matters: - The Emgality market is tied to the growing burden of migraines, a condition that affects more than 1 billion people globally and drives demand for preventive treatment. - Wider use of CGRP-targeting biologics could shift migraine care toward longer-term prevention rather than short-term symptom relief. - The market outlook matters for drug makers, neurologists, and patients looking for more durable migraine control.

What happened: - The Business Research Company released its Global Market Report 2026 on the Emgality market, covering market size, trends, and forecasts for 2026-2035. - The report says Emgality demand is supported by rising migraine prevalence, unmet need in chronic migraine care, clinical success of CGRP-targeting therapies, and growing neurologist acceptance of biologics. - The report identifies North America as the largest regional market in 2025. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. - The company offers a free sample report and a full market report.

The details: - Emgality is a prescription medicine used to prevent migraines and treat episodic cluster headaches in adults. - Emgality is a monoclonal antibody that blocks calcitonin gene-related peptide, or CGRP, a protein linked to migraine attacks and pain signaling. - Blocking CGRP helps reduce the frequency and severity of migraine episodes. - The report says the market’s historical growth has been driven by high migraine prevalence, unmet needs in chronic migraine management, clinical success of CGRP therapies, increased acceptance of biologics by neurologists, and better diagnostic awareness. - The report says future growth will be supported by more chronic migraine patients, expansion into new headache indications, wider acceptance of biologic drugs, improved patient adherence, and higher healthcare spending in neurology. - Key trends include more CGRP inhibitor use, a shift toward preventive migraine treatment, growing demand for long-term headache management, expansion of biologics in neurology, and patient preference for monthly injection regimens. - Migraine Canada reported in May 2023 that migraines affect about 12% of Canadians, or roughly 4.5 million people, and more than 1 billion people worldwide. - Migraine Canada said migraines are more common in women, affecting 30% over their lifetime, compared with 8% of men and 10% of children. - Migraine Canada said about one in four households is affected, and 1% to 2% experience chronic migraines.

Between the lines: - The report points to a market shaped less by one-time treatment demand and more by recurring use, which favors therapies with convenient dosing and long-term adherence. - Monthly injection regimens may appeal to patients and clinicians looking for simpler preventive care, which could help sustain adoption of Emgality and similar drugs. - The emphasis on new headache indications suggests manufacturers are looking for broader uses beyond the core migraine category.

What's next: - The report expects the Emgality market to keep expanding through 2035 as chronic migraine diagnosis improves and biologic adoption widens. - The company says the 2026 edition adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, and updated graphics and tables. - The Business Research Company also lists contact options for expert inquiries and follow-up discussions about the report.

The bottom line: - Emgality sits in a migraine market that is still growing, still underdiagnosed, and increasingly shaped by preventive biologics rather than acute rescue therapy.